Inflammatory Bowel Disease PBMC

Inflammatory Bowel Disease PBMC for Immune-Mediated Inflammatory Disease Research

Inflammatory Bowel Disease PBMC products are sourced from IRB-consented donors clinically diagnosed with inflammatory bowel disease (IBD), processed within 24 hours of collection and cryopreserved in CryoStor CS10. These peripheral blood mononuclear cells support cellular immunology work on IBD-associated immune dysregulation.

IBD Immunology and Why PBMC

IBD is an immune-mediated inflammatory disease of the gastrointestinal tract, comprising Crohn’s disease and ulcerative colitis. It is driven by dysregulated mucosal immunity to the gut microbiota in genetically susceptible individuals rather than by a defined autoantibody.

• Barrier dysfunction and loss of tolerance to commensal microbiota allow inappropriate activation of mucosal T cells, with effector cytokine production sustaining chronic inflammation
• The TNF-alpha and IL-23/Th17 axes are the two best-validated therapeutic pathways, targeted respectively by anti-TNF and anti-IL-12/23 and anti-IL-23 biologics
• Lymphocyte trafficking to the gut, mediated in part by integrin alpha4beta7 and its interaction with MAdCAM-1, is a clinically validated target and is directly measurable on circulating cells
• Genome-wide association studies implicate many loci, with NOD2 variants a well-established contributor to Crohn’s disease susceptibility
• Crohn’s disease and ulcerative colitis differ in distribution, depth of inflammation and treatment response, so subtype selection matters
• PBMC support flow cytometric immunophenotyping including gut-homing marker expression, single-cell sequencing, ex vivo stimulation and functional cytokine assays

Donor Stratification Available

• Subtype: Crohn’s disease versus ulcerative colitis
• Disease activity: active flare versus clinical remission
• Treatment status: treatment-naive, on 5-ASA or thiopurines, on anti-TNF therapy, on anti-IL-12/23 or anti-IL-23 therapy, on integrin blockade, or on JAK inhibitors
• Biologic-naive versus biologic-exposed or primary non-responder
• Disease extent and location, and history of intestinal surgery
• Disease duration since diagnosis
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed IBD donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified IBD diagnosis, with subtype where documented
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Medication history including biologic exposure
• Additional IBD-specific data available upon request

Applications

• Flow cytometric immunophenotyping of T cell, B cell and monocyte subsets
• Gut-homing marker expression analysis, including integrin alpha4beta7
• Th17 and regulatory T cell balance studies
• Ex vivo stimulation and cytokine-release assays
• Single-cell and bulk transcriptomic profiling
• Anti-TNF, anti-IL-23 and JAK inhibitor mechanism-of-action research
• Biologic non-response and treatment-stratification biomarker discovery
• Target identification and validation against matched healthy controls

Other Inflammatory Bowel Disease Specimen Types

• Inflammatory Bowel Disease Plasma
• Inflammatory Bowel Disease Serum
• Inflammatory Bowel Disease Whole Blood
• Inflammatory Bowel Disease Leukopak
• Inflammatory Bowel Disease CD3+ T Cells
• Inflammatory Bowel Disease CD4+ T Cells
• Ulcerative Colitis PBMC

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Inflammatory Bowel Disease PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, availability, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To browse PBMC from other disease states and check live stock status, visit our human PBMC page.